Besides, only in a minority of patients, elevation of pancreatic or liver enzymes was seen, resulting in no pancreatitis and/or cholelithiasis occurrence, which was also verified in a recent meta-analysis showing that treatment with GLP-1-RAs is not associated with increased risk for acute pancreatitis, renal failure, or malignant neoplasms [43]. This evidence concerns the gene GLP1R and cancer.